Ironwood Pharmaceuticals, Inc.
IRWD
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -20.63% | -12.48% | -6.25% | -0.86% | 7.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.63% | -12.48% | -6.25% | -0.86% | 7.83% |
| Cost of Revenue | 22.84% | -64.71% | -45.57% | -58.70% | -86.11% |
| Gross Profit | -21.24% | -1.37% | -0.49% | 6.36% | 19.18% |
| SG&A Expenses | 1.31% | 27.39% | 28.21% | 25.58% | 22.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.44% | 41.83% | 61.68% | 61.82% | 54.00% |
| Operating Income | -50.94% | -58.92% | -53.07% | -41.69% | -21.73% |
| Income Before Tax | 106.88% | 107.90% | 109.92% | -485.37% | -475.59% |
| Income Tax Expenses | -22.96% | -0.13% | 3.34% | -9.24% | 7.93% |
| Earnings from Continuing Operations | 100.09% | 99.68% | 100.76% | -694.27% | -689.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -97.70% | -92.57% | -- | -- |
| Net Income | 100.09% | 99.74% | 101.00% | -678.16% | -672.50% |
| EBIT | -50.94% | -58.92% | -53.07% | -41.69% | -21.73% |
| EBITDA | -50.32% | -58.29% | -52.66% | -41.29% | -21.55% |
| EPS Basic | 100.08% | 99.74% | 101.01% | -671.31% | -668.12% |
| Normalized Basic EPS | -72.32% | -76.44% | -70.45% | -32.29% | -5.48% |
| EPS Diluted | 99.98% | 99.62% | 100.74% | -774.49% | -773.55% |
| Normalized Diluted EPS | -70.04% | -73.61% | -69.17% | -21.49% | 5.14% |
| Average Basic Shares Outstanding | 2.28% | 2.16% | 2.01% | 1.76% | 0.68% |
| Average Diluted Shares Outstanding | -7.09% | -11.37% | -7.32% | -11.50% | -7.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |